>>> BOE Gov Carney: biggest risks to UK financial stability remain on the global

BOE Gov Carney: biggest risks to UK financial stability remain on the global front; losing access to elements of the EU could have outsized effects on UK financial system - comments to lawmakers in London 
- Brexit process has some potential to amplify global financial stability risks; risks around Brexit are greater for continental Europe than for the UK
- It is highly advisable that there should be a Brexit transition phase; if there's no transition deal, BOE will work to mitigate issues as much as possible
- Describing stability of UK financial system post-Brexit as a game of Jenga is a 'decent analogy

Reuters - German SPD says no 'Europe a la Carte' deal for Britain

The top priority in Brexit negotiations for the 27 countries remaining in the European Union must be to hold the bloc together, even if this means suffering one-off economic hits, Germany's Social Democrats (SPD) said in a policy paper.

"Were we to allow a 'Europe à la Carte', this would lead to incalculable domino effects that would threaten the unity of the Union," the parliamentary party of the SPD, junior partner in Chancellor Angela Merkel's ruling coalition, said in the paper.

In the paper, entitled "Strengthening the cohesion of the European Union - our key points for the Brexit negotiations", the SPD said any transitional arrangements for Britain after it leaves the EU should be short-term and tied to tight conditions.

The paper, obtained by Reuters and dated Jan. 9, will be discussed - and likely adopted - by the SPD's parliamentary party on Thursday.

Reuters - UK government expects to lose Brexit trigger case, making contingency

UK government expects to lose Brexit trigger case, making contingency plans - report

The British government expects to lose its legal battle to start the Brexit process without going through parliament, and has drafted versions of a bill to put to lawmakers after the ruling, the Guardian newspaper reported on Tuesday.
The Supreme Court is expected to rule in the next two weeks on whether the government can trigger Article 50 of the European Union's Lisbon Treaty, the first formal step towards leaving the bloc, without first getting parliament's approval.
Citing unnamed sources, the Guardian reported that ministers had privately conceded they were very likely to lose the case, and had drawn up at least two versions of a bill to be presented to parliament after the ruling.
The report also said the government had asked the court for early sight of the ruling before it is made public, to allow for contingency planning.
During the Supreme Court hearing in December, government lawyer James Eadie said that if judges ruled parliament had to give its assent to the triggering of Article 50, the solution would be a "one-line" bill.
The Guardian said ministers were hoping the ruling would allow Prime Minister Theresa May to put forward a short bill or motion, narrowly focused on Article 50, to make it difficult for lawmakers to amend.
Those in favour of a clean break with the European Union are concerned that parliament, where a majority of members were in favour of remaining in the bloc, could seek to water down ministers' plan in pursuit of a so-called "soft Brexit".
The government's opponents in the legal battle argued that triggering Article 50 would nullify the 1972 act of parliament that opened the way for Britain to join the EU, and therefore parliament had to give its assent for its act to be undone.
London's High Court backed that argument, prompting the government to appeal to the Supreme Court, Britain's highest judicial body, in December.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • NVDQ -17.3%, (sees Q4 rev below consensus; sees FY17 rev below consensus), SVU -8.1%, SIG -4.6%, BWA -1.9%, LMNR -1.6%
M&A news:
  • ADM -5.6% (to acquire Crosswind Industries; terms not disclosed)
Select pharma related names showing weakness:
  • BMY -3.6%, AZN -1.6%, SHPG -1.1%
Other news:
  • SGNL -12.8% (pulling back following recent strength)
  • ETRM -11.2% (pulling back following recent strength)
  • GNVC -7.4% (pulling back following recent strength)
  • PTN -5.3% (Palatin Technologies to hold call following closing of licensing agreement with AMAG Pharmaceuticals for North American rights to Rekynda)
  • PFGC -5% (prices 10 mln common stock offering by certain of its stockholders, including affiliates of The Blackstone Group (BX) at $22.85/share )
  • BRG -4.7% (commenced a public offering of 4,000,000 shares of its Class A common stock)
  • TERP -4.5% (Brookfield Asset Management affirms 12.12% active stake, discloses the submission of alternative proposals to the company's advisors with respect to a potential transaction involving the company and/or TerraForm Global)
  • PE -2.9% (announces Midland Basin and Delaware Basin acquisitions and introduces 2017 capital program and operating guidance; expects ~60% annual production growth in 2017; commenced an underwritten public offering of 20,000,000 shares of Class A common stock), .
Analyst comments:
  • HIMX -2.5% (downgraded to Neutral from Buy at ROTH Capital)
  • WUBA -1.6% (initiated with a Underperform at Bernstein)
  • JD -1% (initiated with an Underperform at Bernstein )
  • C -0.8% (downgraded to Sell at UBS)
  • BIDU -0.7% (initiated with a Underperform at Bernstein)

WSJ : Samsung Heir Named as Bribery Suspect in Influence-Peddling Investigation

Samsung Heir Named as Bribery Suspect in Influence-Peddling Investigation
Lee Jae-yong to be summoned for questioning Thursday

SEOUL—The third-generation heir of South Korea’s Samsung conglomerate will be questioned in relation to suspected bribery, prosecutors said, drawing the country’s biggest and most powerful business group deeper into an unfolding political scandal that has already led to the impeachment of the president.

Lee Jae-yong, the 48-year-old heir-apparent to the Samsung empire, will be summoned for questioning on Thursday morning by special prosecutors, a spokesman for the special prosecutors’ office said Wednesday.

The special prosecutors’ office also called on lawmakers to report Mr. Lee for allegedly lying under oath while testifying last month at a legislative hearing on the corruption scandal. Special prosecutors would then be able to investigate charges of perjury, according to Hong Jung-seok, a spokesperson for the special prosecutors.

A spokeswoman at Samsung declined to comment or make Mr. Lee available for comment.

The special prosecutors’ office was created by the National Assembly late last year after allegations of high-level corruption involving a longtime confidante of President Park Geun-hye and the country’s biggest conglomerates.

Prosecutors are looking into whether conglomerates such as Samsung, Hyundai and LG, which donated millions of dollars to two foundations allegedly controlled by Choi Soon-sil, Ms. Park’s friend, expected political favors in return. Ms. Choi is alleged to have exerted unusual control over government decisions from behind the scenes. She has denied wrongdoing.

Top executives at Hyundai and LG, at a legislative hearing, didn’t deny the contributions, but said that they had little choice but to give.

In Samsung’s case, prosecutors have raised questions about whether the government-backed National Pension Service, the world’s third-largest pension fund and the largest shareholder in many South Korean stocks, voted in favor of an $8 billion merger of two Samsung affiliates in 2015 in exchange for donations to Ms. Choi. The merger helped Mr. Lee solidify control over smartphone maker Samsung Electronics Co. Samsung declined to comment on the allegations.

Samsung topped the list of conglomerates that donated to Ms. Choi’s two foundations, contributing 20.4 billion Korean won ($17 million) in total.

Prosecutors also appeared to be looking at separate payments made by Samsung to other entities owned by Ms. Choi and her daughter Chung Yoo-ra, an equestrian-dressage athlete who won a gold medal in the 2014 Asian Games.

Ms. Choi, who is in custody, has denied wrongdoing, while a lawyer for Ms. Chung in Denmark, where she is being detained, has also denied wrongdoing. Ms. Chung said in an interview with Korean reporters in Denmark that she wasn’t aware of her mother’s affairs.

In 2015, three months after Samsung completed its closely watched merger over the objections of minority shareholders including U.S. hedge fund Elliott Management Corp., Samsung signed a deal with Core Sports International GmbH, a small sports-consulting company based in Dillenburg, Germany, about 60 miles north of Frankfurt, to train equestrian athletes.

A contract reviewed by The Wall Street Journal between Samsung and Core Sports, later renamed Widec Sports, shows Samsung agreed to provide about $18 million to train equestrian athletes to compete in the 2018 Asian Games and World Equestrian Games.

The company was owned by Ms. Choi and her daughter, according to Park Sung-kwan, a Frankfurt-based lawyer and former managing director of Core Sports who co-signed the contract with Samsung in 2015.

The contract also was signed by Park Sang-jin, a Samsung Electronics president who since 2015 has been head of the Korea Equestrian Federation, where Ms. Choi’s daughter is a registered athlete. Prosecutors raided the equestrian federation’s office in November last year.

During last month’s hearing, Mr. Lee, the Samsung heir, acknowledged that Samsung had paid Widec 3.7 billion won ($3.1 million), but said that he wasn’t aware of who Ms. Choi or her daughter were at the time.

Samsung also purchased a horse for Ms. Choi’s daughter, estimated to cost about 1 billion won, Mr. Lee testified.

Between September 2015 and February 2016, Samsung contributed 500 million won to the Korea Winter Sports Elite Center, according to a project proposal submitted by the sports center that was reviewed by the Journal. The sports center was run by Ms. Choi’s niece, Jang Si-ho, who testified at last month’s legislative hearing that creating the sports center was Ms. Choi’s idea.

The sports center didn’t respond to multiple calls seeking comment.

At last month’s legislative hearing, Mr. Lee denied that Samsung received favors in return for making any contributions. Mr. Lee further dismissed the notion that the controversial merger was carried out to increase his control over Samsung Electronics. “The merger between the two companies was not related to my succession, said Mr. Lee.

This is the first time Mr. Lee has been summoned by the special prosecutors’ team after government prosecutors questioned him in November last year. Earlier this week, prosecutors had summoned two of Mr. Lee’s top lieutenants, including G.S. Choi, one of Samsung’s longest-serving senior executives, for questioning.

Historically, the heads of South Korean conglomerates have enjoyed lenient treatment from the judicial system, in part because the conglomerates are a key pillar of the national economy. As public anger against the conglomerates has risen in recent years, however, convictions have become more common, though suspended sentences and presidential pardons mean few tycoons have had to spend time behind bars.

Mr. Lee’s father, second-generation chairman Lee Kun-hee, was convicted twice—in 1996 for bribing the president, and in 2008 for embezzlement and tax evasion. Each time, he was given suspended sentences and then pardoned by the president.

>>> Signet Jewelers Cuts Q4 Guidance Range (SIG)

Signet Jewelers Cuts Q4 Guidance Range --> -3.96% in premarket only 5,6k traded
Signet Jewelers (SIG 87.46) is the world's largest retailer of diamond jewelry. The holidays, then, are quite literally its time to shine in the retail industry. The holiday sales update provided by the company this morning, however, indicated that its performance lacked some usual sparkle.
Signet operates approximately 3,600 stores under the name brands of Kay Jewelers, Zales, Jared The Galleria of Jewelry, H. Samuel, Ernest Jones, Peoples and Piercing Pagoda. These stores are situated in mall and off-mall locations. Each of those brands, incidentally, saw same-store sales decline this holiday season, with the lone exception of Piercing Pagoda (+4.2%).
Many warnings have been heard already from mall-based retailers, mostly from apparel companies, which have been afflicted by soft customer traffic. Many of those same warnings, though, included an upbeat assessment at least of the company's e-commerce business. In Signet's case, however, the sales downturn it saw in the holiday period was attributed mostly to the underperformance of its Sterling division e-commerce business.
Briefly, Signet's holiday season summary featured a 4.6% decrease in same-store sales versus a 5.1% increase in the same period a year ago and a 5.1% decrease in total sales versus a 5.3% increase in the year-ago period
The downturn in the jeweler's sales prompted a culling of its fourth quarter guidance ranges. In particular, Signet now expects adjusted earnings to range from $4.00 to $4.05 per share, versus prior guidance of $4.00 to $4.20, and its same-store sales to be down 4.3% to 4.8%, compared to a prior view that they would be down 2.0% to 4.0%.
Signet said its merchandise categories and collections were broadly lower in the mall and e-commerce selling channels, while select merchandise and other selling channels performed relatively well.
The source of dismay for many investors today was the acknowledgment that its e-commerce sales in the holiday season were down 2.4% to $142.5 million. That decline was blamed on poorly performing enhancements made recently to its e-commerce systems across all Sterling Jewelers divisions store banners, which use a common platform and accounted for approximately 62% of Signet's total fourth quarter sales.
Reportedly, those enhancements failed to adequately deal with high holiday volume, which resulted in customer communication issues and purchasing disruptions.
Signet, then, seems to have hurt its own cause at a time when the sales environment for mall-based retailers was already extremely challenging due, in part, to the rise of online competition. Ironically, Signet provided online competition for itself with its technical shortcomings.
The jewelry retailer said it is working to improve the overall customer digital journey, yet that clarification isn't helping its stock at the moment, which is down 6% in pre-market action on the heels of an 11% decline it has registered since December 9.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • ICHR +9%, (sees Q4 revs $131 mln vs $117.90 mln Capital IQ Consensus Estimate, expects Q1 sales to be higher than Q4)
  • MSM +2.5%, DE +1.2%, (light volume; releases December retail sales update)
  • MX +0.8%, (MagnaChip Semi reports prelim Q4 sales at high end of guidance / above consensus; announces proposed $65 mln private offering of exchangeable senior notes and stock repurchase)
  • VRX +0.5%, (reiterates FY16 guidance)
M&A news:
  • DSCI +41% (to be acquired by Integra LifeSciences (IART) for $7.00 per share)
  • RAD +4% (NY Post discusses that regulators might complete review of Walgreens (WBA) and Rite Aide (RAD) merger before President Obama leaves office), ;
Other news:
  • BIOC +43.1% (continued strength)
  • ENPH +22.1% (announces a $10 mln private placement of its common stock to T.J. Rodgers and John Doerr, chairman of Kleiner Perkins Caulfield & Byers)
  • TGTX +10% (completion of enrollment in part 1 of its phase II study of TG-1101)
  • AKAO +9.3% (Baker Bros discloses 13.1% passive stake)
  • SGMO +6.8% (granted orphan designation by the FDA for its compound for the treatment of mucopolysaccharidosis type I )
  • CTSO +6.3% (light volume; CytoSorbents and the U.S. Air Force determine to close the Company-sponsored, 30 patient, single site, randomized controlled human pilot study of the CytoSorb product to evaluate patients with severe trauma and rhabdomyolysis)
  • ARLZ +4.2% (USPTO has issued patent covering Yosprala which will expire in late 2032 with possible patent term adjustment into early 2033)
  • MRK +3.1% (receives FDA acceptance of supplemental biologics license application for Keytruda in combo with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer)
  • RDHL +2.9% (RHB-104 has been granted QIDP designation by the FDA for the treatment of Nontuberculous Mycobacteria infection)
  • UAL +2.8% (expects Q416 consolidated passenger unit rev to decline 1.25-1.75% (prior 3-4%) compared to Q416)
  • GST +2.1% (declares special cash dividends on 8.625% Series A Preferred Stock and 10.75% Series B Preferred Stock; enters into related amendment of credit agreement)
  • AAL +1.6% (reports December traffic, raises Q4 TRASM, pre-tax margin; RPMs -0.8% y/y)
  • MYL +1% (FDA has accepted Mylan's biologics license application for MYL-1401O, a proposed biosimilar trastuzumab)
Analyst comments:
  • KERX +4.8% (upgraded to Neutral from Sell at Citigroup)
  • BT +2.7% (upgraded to Overweight from Equal Weight at Morgan Stanley)
  • ESV +1.7% (upgraded to Buy from Neutral at Citigroup)
  • WRD +1.7% (initiated with a Strong Buy at Raymond James)
  • PANW +0.8% (initiated with Outperform ratings at Wells Fargo)